Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TapImmune appoints David Laskow-Pooley to board

This article was originally published in Scrip

Executive Summary

TapImmune, an immunotherapy company specializing in the development of therapies for cancer and infectious disease, has appointed David Laskow-Pooley to its board of directors. Mr Laskow-Pooley is currently CEO of London Pharma, a clinical-stage company re-purposing approved drugs through novel drug delivery technologies, and is the co-founder of Pharmafor. He was formerly managing director (UK) of Nasdaq-listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts